R.H. Bluestein & Co’s Novavax NVAX Stock Holding History

R.H. Bluestein & Co’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6,000	Closed	-$1.27M	–	436
2021 Q2	$1.27M	Buy	+6,000	New	+$1.1M	0.05%	98

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

R.H. Bluestein & Co's NVAX Position: Q3 2021 in Review

R.H. Bluestein & Co sold out of Novavax (NVAX) in Q3 2021, closing a stake of 6,000 shares — an estimated $1.27M sold.

R.H. Bluestein & Co first reported a position in NVAX in Q2 2021 and held it in 1 quarter. The position peaked at $1.27M in Q2 2021. 442 funds tracked by Wall St. Rank hold NVAX as of Q3 2021.

R.H. Bluestein & Co reported no remaining Novavax position as of Q3 2021 after selling out during the quarter.
R.H. Bluestein & Co sold 6,000 Novavax shares in Q3 2021, an estimated $1.27M.
R.H. Bluestein & Co first reported a position in Novavax in Q2 2021 and held it in 1 quarter.
R.H. Bluestein & Co's Novavax position peaked at $1.27M in Q2 2021.
442 funds tracked by Wall St. Rank held Novavax as of Q3 2021.

Based on R.H. Bluestein & Co's 13F filing for Q3 2021, filed 12 Nov 2021.